Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

basic toxicokinetics
Type of information:
other: Toxicokinetic Assessment
Adequacy of study:
key study
Study period:
Not Reported
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: This toxicokinetics assessment was conducted by a capable person in a GLP facility.

Data source

Reference Type:
study report
Report date:

Materials and methods

Objective of study:
Principles of method if other than guideline:
This desk-based study used existing physico-chemical, environmental fate and toxicological data to assess the toxicokinetics of the test item.
GLP compliance:

Test material

Constituent 1
Details on test material:
Idenitification of test item (as cited in study report): NALCO 01WC026/PSO

Results and discussion

Any other information on results incl. tables

The acute and dermal toxicity of NALCO 01WC026 is low, with the LD50 being > 2000 mg/kg body weight in both cases. The 28 -day toxicity study also revealed that NALCO 01WC026 has a relatively low toxicity, with a NOAEL of 1000 mg/kg/day. Therefore an extensive toxicokinetic assessment is considered of limited value. Below, an assessment of the anticipated toxicokinetic behaviour of NALCO 01WC026 is given.

The water solubility of Nalco 01WC026/PSO is high (> 1000 g/L), caused by the presence of the strongly polar phosphorous and carboxylic acid groups. The strong polarity of these groups makes it very unlikely that this compound easily passes the gastrointestinal wall. Therefore, it is to be expected that the oral bioavailability, and thus systemic exposure, of NALCO 01WC026/PSO will be low.

In the case absorption of NALCO 01WC026/PSO occurs, extensive conjugation of the carboxylic acid groups is anticipated, but also oxidation of the aliphatic groups followed by a rapid sulphation or glucuronidation may occur. The resulting metabolites, as well as the parent compound will be extensively excreted via urine and/or bile.

NALCO 01WC026/PSO will show a low volume of distribution equalling extracellular body water (approximately 0.7 litres per kg body weight). Accumulation is fatty tissues is not anticipated. The plasma protein binding is expected to be low.

Since the bioavailability of dermally applied compounds can be assumed to be zero for substances with a log Pow between -1 and over 5 or a relative molecular mass over 700, it is not expected that NALCO 01WC026 will be absorbed through the skin.

Based on the expected kinetic behaviour in the body, as described above, NALCO 01WC026/PSO will hardly be absorbed after oral administration, because of the presence of strongly polar groups in the molecule. If absorption occurs, NALCO 01WC026/PSO will be extensively metabolised in the liver. Therefore, accumulation in the body during prolonged exposure is not anticipated.

This is supported by the absence of systemic toxicity observed in both the acute and subacute toxicity studies.

Applicant's summary and conclusion

Interpretation of results (migrated information): no bioaccumulation potential based on study results